DarioHealth (DRIO) Fundamental Analysis: Revenue, Earnings & Valuation

1.01 / 10

Underperform

Fundamental score is 1.01/10 (Underperform). Profit‑MV and Asset‑MV show modest upside, yet cash‑related metrics and ROE are negative, dragging the rating. Overall financial health appears weak despite slight profit advantage.

Analysis Checks(4/10)

ROA (%)

Value-36.44

Score1/3

Weight16.58%

1M Return-1.19%

Annualized return on equity (%)

Value-88.23

Score1/3

Weight27.44%

1M Return-2.02%

Profit-MV

Value0.41

Score2/3

Weight-55.38%

1M Return3.26%

Cash-UP

Value-0.01

Score2/3

Weight50.50%

1M Return-3.92%

Annualized net profit margin on total assets (%)

Value-36.44

Score1/3

Weight16.58%

1M Return-1.19%

ROE (diluted) (%)

Value-90.89

Score1/3

Weight19.24%

1M Return-1.41%

Asset-MV

Value-0.48

Score2/3

Weight-59.19%

1M Return3.42%

ROE (%)

Value-88.23

Score1/3

Weight27.44%

1M Return-2.02%

Cash-MV

Value-0.09

Score1/3

Weight43.54%

1M Return-3.56%

Net profit / Total profit (%)

Value100.25

Score2/3

Weight13.24%

1M Return-0.89%

Is DRIO undervalued or overvalued?

DRIO scores 1.01/10 on fundamentals and holds a Premium valuation at present. Backed by its -88.23% ROE, -186.56% net margin, -0.96 P/E ratio, 0.87 P/B ratio, and 17.52% earnings growth, these metrics solidify its Underperform investment rating.